Current Trials
ACTIVE CLINICAL STUDIES AT THE CRCNJ
To find out if you’re eligible, contact us at one of the numbers below or click on the link to the trial of interest, complete the online form, and we will contact you.
SPRINGFIELD OFFICE: 973-850-4622
RIDGEWOOD OFFICE: 201-850-4622
Actively Enrolling Memory Studies
A study evaluating the efficacy and safety of MK-2214 in patients with early Alzheimer’s disease (Merck 2214-004)
Sponsor: Merck
CRCNJ Location: Springfield and Ridgewood
This is a Phase II randomized, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of MK-2214 in participants with Early Alzheimer's disease.
clinicaltrials.gov.
A double-blinded study of the efficacy and Safety of Trontinemab in patients with early symptomatic MCI to mild dementia due to Alzheimer’s disease (Trontier I & II)
Sponsor: Hoffman La Roche
CRCNJ Location: Springfield and Ridgewood
Trontier I WN45443/Trontier II WN45447: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)
clinicaltrials.gov.
A prescreening study with a blood biomarker (Traveller)
SPONSOR: Roche
The Traveller study is a prescreening study to identify potential patients for upcoming clinical trials with investigational medication. Patients will undergo cognitive and blood biomarker testing to see if they are a potential candidate for future studies.
A study investigating if an epigenetic regulatory may improve cognitive function (ONO)
Sponsor: ONO Pharmaceuticals
Location: Springfield
This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with mild to moderate Alzheimer's disease dementia.
clinicaltrials.gov.
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease (Retain Study)
SPONSOR: Janssen Pharmaceuticals
Location: Springfield
A multicenter, randomized, placebo-controlled, double blinded and parallel group study that assesses the efficacy of a Phosphorylated Tau targeted active immunotherapy in participants 55-75 years old with Pre-Clinical Alzheimer's disease.
clinicaltrials.gov.
A parallel group study to evaluate the safety and efficacy of KarXT + KarX-EC for patients of cognitive impairment associated with Alzheimer’s disease (MINDSET 2)
Sponsor: Bristol-Myers Squibb
Location: Springfield
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 2)
clinicaltrials.gov.
Actively Enrolling Liver Disease Studies
A study for individuals with Metabolic Dysfunction who have a risk of developing adverse liver outcomes (MALO)
Sponsor: Eli Lilly
Location: Ridgewood
N1T-MC-MALO: A master protocol for a randomized, controlled, clinical trial of multiple pharmacologic agents in adult participants with metabolic dysfunction-associated steatotic liver disease who are at increased risk of developing major adverse liver outcomes
clinicaltrials.gov.
A study evaluating safety ad efficacy of a drug in patients with MASH and fibrosis (AKERO)
Sponsor: Akero Therapeutics
Location: Ridgewood
A phase III, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Efruxifermin in subjects with non-cirrhotic nonalcoholic steatohepatitis
(NASH) metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis
Active But Closed to Enrollment
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6: AACQ)
SPONSOR: Eli Lilly
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
SPONSOR: Acumen Pharmaceuticals
The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
clinicaltrials.gov.
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
SPONSOR: Eli Lilly
TRAILRUNNER-ALZ 1 is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of remternetug in participants with early symptomatic AD. Participants will receive remternetug or placebo administered via subcutaneous injection or intravenous infusion.
clinicaltrials.gov.
CLOSED TO ENROLLMENT
A Study of Remternetug Versus Placebo in Participants at Risk Early Alzheimer'd Disease (Trailrunner ALZ 3 - LAKI)
SPONSOR: Eli Lilly
The purpose of this double blinded study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
clinicaltrials.gov.
CLOSED TO ENROLLMENT
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
SPONSOR: Eli Lilly
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
clinicaltrials.gov.
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
SPONSOR: Eli Lilly
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease.
clinicaltrials.gov.
CLOSED TO ENROLLMENT
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study)
SPONSOR: Cognito Therapeutics
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 345 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State Exam (MMSE).
clinicaltrials.gov.
Click here to make an appointment or call 973-850-4622 to learn more about how The CRCNJ can help.
